Bortezomib for the treatment of relapsed or refractory follicular non-Hodgkin's lymphoma
Status Suspended
Decision Selected
Process STA pre-2018
Referral date 01 November 2010
Topic area
  • Cancer

Scoped within Batch 14

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC
2nd appraisal committee meeting TBC

Project Team

Communications manager: Alice Law
Executive Lead: TBC
Project manager: Bijal Joshi
Technical Lead: Raisa Sidhu


Key events during the development of the guidance:

Date Update
22 March 2012 The technology appraisal has been suspended. This is due to ongoing regulatory discussions regarding the licence for this drug.
2 September 2011

Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early March 2012 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid May 2012.

22 February 2011

Following on from advice received from the manufacturer, the dates for this appraisal will be confirmed once regulatory approval timelines are established

For further information on our processes and methods, please see our CHTE processes and methods manual